ClinicalTrials.Veeva

Menu
C

Center for Emotional Fitness | Cherry Hill, NJ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dasotraline
SPD489
Azetukalner
Cariprazine
Lisdexamfetamine dimesylate
Troriluzole
Rapastinel
BI 1358894
Brexpiprazole
OPC-34712

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 65 total trials

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) (X-CEED)

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult part...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo
Drug: Azetukalner

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Azetukalner
Drug: Placebo

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Invitation-only
Major Depressive Disorder
Drug: Azetukalner

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive...

Active, not recruiting
Major Depressive Disorder (MDD)
Drug: Ropanicant
Drug: Placebo

Trial sponsors

Otsuka logo
Sumitomo Pharma logo
Shire logo
Pfizer logo
Boehringer Ingelheim logo
Biohaven logo
Indivior logo
Allergan logo
X
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems